Multispecialty - GSK

Multispecialty

Status:

Enrolling

ClinicalTrials.gov:

NCT05878717

A Phase 2/3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with systemic sclerosis associated interstitial lung disease (SSc-ILD)

Phase

phase 2/3

Condition

Insterstitial lung disease